Genzyme Corporation Online Newsroom |

News

E-Mail Print Text Size

Featured Press Releases

April 25, 2013
Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today positive top-line results from the TOPIC trial for AUBAGIO (teriflunomide). The trial was designed to assess whether early initiation of AUBAGIO (teriflunomide) in patients who experienced their first...
April 18, 2013
Genzyme Convenes 13th European Fabry Disease Roundtable
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced that the 13th European Fabry Disease Roundtable will take place April 19 and 20 in Madrid, Spain. The Roundtable is a scientific meeting sponsored by Genzyme that brings together more than 200...
April 8, 2013
Genzyme’s Once-daily, Oral AUBAGIO® (teriflunomide) Approved in Argentina for the Treatment of Relapsing Multiple Sclerosis
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) has approved once-daily, oral AUBAGIO® 14 mg as a new treatment indicated for patients with relapsing forms of...
March 22, 2013
Genzyme Receives Positive CHMP Opinion in the European Union for Once-daily, Oral AUBAGIO® to Treat Relapsing-Remitting Multiple Sclerosis
Genzyme, a Sanofi Company (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion regarding the approval of once-daily, oral AUBAGIO® (teriflunomide)...

Featured Videos

The Making of Protein Therapies

Genzyme - The Future of Hope

Please visit Genzyme's YouTube Channel to view all videos.

Leadership

Christopher A. Viehbacher
Chief Executive Officer, Sanofi; Chairman, Genzyme

Christopher Viehbacher, born March 26, 1960, holds German and Canadian nationalities. He is a graduate of the Queens University (Ontario - Canada) and a certified public accountant. More...

David Meeker, M.D.
President; Chief Executive Officer

David Meeker, 57, was appointed CEO of Genzyme in October 2011. In his career with Genzyme, he has held key positions of increasing responsibility, most recently as Chief Operating Officer. More...

Media Resources

Tweets

Great @PM360online article w examples of patient-centric initiatives, including our Facing Fabry Together film http://t.co/3Pipplidns-1 hour 41 min ago

Excited to begin a Ph1B clinical trial for Niemann-Pick type B! First patients were infused this week. #RareDisease-4 hours 37 min ago

.@WorldMSDay is one week from today! Share the motto you live by to help raise awareness of #MS http://t.co/m93PEE3gfA-1 day 5 hours ago

One step closer to #NewbornScreening for Pompe disease! We strongly support this recommendation http://t.co/N2qsdkzpSy #RareDisease-1 day 23 hours ago

12 Genzyme runners, 200 miles, 24 hours - it's #reachthebeach! Go Team Genzyme! #BostonStrong http://t.co/sGVjyNr3n2-6 days 2 hours ago

Social Media

Latest Press Releases

Keep up to date by reading the latest press releases for Genzyme.

Interactive Timeline

Explore Genzyme’s history, year-by-year, including key milestones, photographs, and video clips.

Launch the timeline

Targeting Unmet Needs

View our specialized portfolio of therapies, which provide personalized treatment for patients with rare diseases.

See our products list

Jobs at Genzyme

Learn about job opportunities around the world for those who are motivated by the prospect of changing patients’ lives for the better.

Search jobs now

Business Wire NewsHQ℠